IGF-1 DES research and evidence overview

Des(1-3)IGF-1 is preclinical. Its biology was characterized in the 1980s and 1990s in cell culture and animal models, and the review literature from that period noted that clinical opportunities "have not yet been evaluated" (PMID 8930132). Three decades later that remains true: there is no approved indication, no published human trial, and no human safety dataset. Everything credible said about it comes from cells, rodents, pigs, and marmosets.

What distinguishes it from most compounds in this catalog is that it is not an invented molecule at all.

Des(1-3)IGF-1 is human IGF-1 missing the first three N-terminal residues—the tripeptide Gly-Pro-Glu. It has been isolated from bovine colostrum, human brain, and porcine uterus, and is thought to arise from post-translational cleavage of intact IGF-1 rather than being manufactured by design (PMID 8930132).

The functional consequence traces to a single lost residue. Removing the glutamate at position 3 sharply reduces affinity for the IGF-binding proteins that normally sequester circulating IGF-1, leaving more peptide free to engage the receptor. This is the same mechanism the engineered analogue Long-R3-IGF-1 exploits deliberately—des(1-3) is what nature arrived at first.

The commonly cited figure is that des(1-3)IGF-1 is roughly tenfold more potent than IGF-1. That number comes from cultured cells, where it stimulates hypertrophy and proliferation at correspondingly lower concentrations, and it is a consequence of reduced binding-protein interaction rather than any change in receptor affinity (PMID 8930132). In whole animals the advantage narrows and changes character. A comparative study in pigs and marmosets (PMID 9415072) ranked des(1-3)IGF-1 as the most potent of five IGF-1 forms tested for acute glucose lowering—but the margin over native IGF-1 was 2- to 3-fold at the glucose nadir, not tenfold. Its cumulative four-hour hypoglycemic effect was roughly 4- to 8-fold greater, because the suppression lasted much longer rather than going much deeper.

Two lessons sit inside that discrepancy. Potency ratios do not survive the move from a dish to a bloodstream unchanged, and the endpoint that the animal data actually quantified for this molecule is blood glucose.

One finding in the des(1-3) literature is genuinely distinctive: when administered in vivo, the increased potency is partly retained, with anabolic effects "particularly evident in gut tissues" (PMID 8930132). The 1996 review proposed catabolic states and inflammatory bowel disease as the plausible clinical targets on that basis—not muscle growth in healthy adults, which is the use the peptide is marketed for today.

That mismatch between the literature's own suggested direction and the market's is worth noting. The research rationale pointed at the intestine; the sales pitch points at the gym.

For des(1-3)IGF-1, most claims can be traced back to a small number of 1990s papers, and the useful checks are simple. Was the measurement in cells or in an animal? Was the comparator native IGF-1 at an equipotent dose or the same dose? Was glucose monitored? The literature is old, thin, and honest about its own limits—the review that established the tenfold figure also stated plainly that no clinical evaluation had been done.